Markets:

Overview

News

Currencies

International

Treasuries

Nektar Therapeutics - Common Stock (NQ:NKTR)

71.33 +0.33 (+0.46%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Nektar Therapeutics - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

What 4 Analyst Ratings Have To Say About Nektar Therapeutics ↗

March 15, 2022

Analysts have provided the following ratings for Nektar Therapeutics (NASDAQ:NKTR) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish...

Via Benzinga

Where Nektar Therapeutics Stands With Analysts ↗

March 15, 2022

Nektar Therapeutics (NASDAQ:NKTR) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 15, 2022 ↗

March 15, 2022

Upgrades For Turquoise Hill Resources Ltd (NYSE:TRQ), BMO Capital upgraded the previous rating of Underperform to Market Perform. Turquoise Hill Resources earned $0.78 in the...

Via Benzinga

10 Biggest Price Target Changes For Tuesday ↗

March 15, 2022

Wells Fargo cut the price target on Coupa Software Incorporated (NYSE: LPI) from $190 to $80. Laredo Petroleum shares fell 29.8% to $63.10 in pre-market trading.

Via Benzinga

Why is Nektar Therapeutics (NKTR) Stock Down Today? ↗

March 14, 2022

Nektar Therapeutics is down big today after ending some of its clinical trials. What's going on with NKTR stock?

Via InvestorPlace

Earnings Scheduled For February 28, 2022 ↗

February 28, 2022

Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (...

Via Benzinga

96 Biggest Movers From Yesterday ↗

March 15, 2022

Gainers Volt Information Sciences, Inc. (NYSE: VOLT) shares surged 94.7% to close at $5.88 on Monday after the company announced it would be acquired for $6 per share. Incannex...

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

February 04, 2022

On Friday, 209 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Meta Platforms (NASDAQ:FB) was the largest firm on a market cap...

Via Benzinga

Mid-Afternoon Market Update: Dow Turns Negative; Turquoise Hill Resources Shares Spike Higher ↗

March 14, 2022

U.S. stocks turned lower toward the end of trading on Monday as the Dow Jones dropped 100 points, after surging more than 400 points earlier during the session. The Dow...

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

March 14, 2022

Gainers Incannex Healthcare (NASDAQ:IXHL) stock moved upwards by 48.0% to $20.95 during Monday's regular session. The company's market cap stands at $1.0 billion....

Via Benzinga

Knightscope News: Why Is KSCP Stock Up Today? ↗

March 14, 2022

Knightscope (KSCP) stock is on the move Monday following news that the company signed onto a new real estate development project.

Via InvestorPlace

Mid-Day Market Update: Markets Mixed; Nasdaq Drops Over 100 Points ↗

March 14, 2022

The Nasdaq index turned lower midway through trading, losing more than 100 points on Monday. The Dow traded up 0.61% to 33,143.88 while the NASDAQ fell 1.13% to 12,698.26....

Via Benzinga

50 Stocks Moving In Monday's Mid-Day Session ↗

March 14, 2022

Gainers Volt Information Sciences, Inc. (NYSE: VOLT) shares jumped 95.2% to $5.89 after the company announced it would be acquired for $6 per share. AgriFORCE Growing Systems,...

Via Benzinga

Bristol Myers, Nektar Melanoma Doublet Therapy Trial Fails To Show Clinical Benefit ↗

March 14, 2022

Bristol Myers Squibb Co (NYSE: BMY) and Nektar Therapeutics (NASDAQ: NKTR) have an update following the first analysis of the Phase 3 PIVOT IO-001 study of...

Via Benzinga

Mid-Morning Market Update: Markets Open Higher; Crude Oil Dips 8% ↗

March 14, 2022

U.S. stocks opened on a strong note this morning, with the Dow Jones gaining 300 points on Monday. Following the market opening Monday, the Dow traded up 0.99% to 33,269.95 while...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 14, 2022 ↗

March 14, 2022

Upgrades Janney Montgomery Scott upgraded the previous rating for Enova International Inc (NYSE:ENVA) from Neutral to Buy. Enova International earned $1.61 in the fourth quarter,...

Via Benzinga

Nektar Therapeutics Loses Half Its Value As Bristol Myers-Paired Melanoma Test Flops ↗

March 14, 2022

Sentiment was low heading into the study and analysts aren't hopeful for other tests.

Via Investor's Business Daily

Why Nektar Therapeutics Shares Are Falling Today ↗

March 14, 2022

Nektar Therapeutics (NASDAQ: NKTR) is trading significantly lower Monday morning after the company's Phase 3 PIVOT trial, in combination with Bristol-Myers Squibb Co (...

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

March 14, 2022

Gainers Erytech Pharma (NASDAQ:ERYP) stock rose 18.7% to $1.65 during Monday's pre-market session. The market value of their outstanding shares is at $51.1 million....

Via Benzinga

Bristol Myers Squibb and Nektar Announce Update on Phase 3 PIVOT IO-001 Trial Evaluating Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab) in Previously Untreated Unresectable or Metastatic Melanoma

March 14, 2022

From Bristol Myers Squibb

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For March 9, 2022 ↗

March 09, 2022

Upgrades Roth Capital upgraded the previous rating for Hudson Technologies Inc (NASDAQ:HDSN) from Neutral to Buy. For the fourth quarter, Hudson Technologies had an EPS of $0.13,...

Via Benzinga

Nektar Therapeutics: Q4 Earnings Insights ↗

February 28, 2022

Nektar Therapeutics (NASDAQ:NKTR) reported its Q4 earnings results on Monday, February 28, 2022 at 04:00 PM. Here's what investors need to know about the announcement....

Via Benzinga

Earnings Outlook For Nektar Therapeutics ↗

February 25, 2022

Nektar Therapeutics (NASDAQ:NKTR) is set to give its latest quarterly earnings report on Monday, 2022-02-28. Here's what investors need to know before the announcement. Analysts...

Via Benzinga

Big Trend Occurring in Triple-Negative Breast Cancer Treatment Is The Shift Towards Combination Therapy

December 10, 2021

Palm Beach, FL – December 10, 2021 – FinancialNewsMedia.com News Commentary – Ongoing advancements in cancer research continue to lead to the introduction of newer and better treatment options...

Via FinancialNewsMedia

7 Drug Stocks to Buy Now While They’re Still on Sale ↗

November 30, 2021

Covid-19 stocks soared to unsustainable highs as investors ignored drug stocks with a deep pipeline of products for the decade ahead.

Via InvestorPlace

Topics Supply Chain

The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More ↗

December 06, 2021

The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2021 ↗

November 08, 2021

Upgrades For Nektar Therapeutics (NASDAQ:

Via Benzinga

The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance ↗

November 10, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus MorphoSys COO To Leave To Pursue Other Opportunities MorphoSys AG (NASDAQ:...

Via Benzinga

The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More ↗

November 08, 2021

Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out...

Via Benzinga

92 Biggest Movers From Friday ↗

November 08, 2021

Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares jumped 99.8% to close at $9.99 on Friday. Mainz Biomed priced its initial public offering of 2 million ordinary shares at $5, the...

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Nektar Therapeutics - Common Stock (NQ:NKTR)

All News about Nektar Therapeutics - Common Stock

Starting at $3.75/week.

Subscribe Today